;PMID: 7985080
;source_file_1414.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..31] = [t:0..31]
;1)sentence:[e:36..136] = [t:36..136]
;2)section:[e:140..198] = [t:140..198]
;3)section:[e:202..287] = [t:202..287]
;4)sentence:[e:291..302] = [t:291..302]
;5)sentence:[e:303..426] = [t:303..426]
;6)sentence:[e:427..544] = [t:427..544]
;7)sentence:[e:545..553] = [t:545..553]
;8)sentence:[e:554..669] = [t:554..669]
;9)sentence:[e:670..876] = [t:670..876]
;10)sentence:[e:877..995] = [t:877..995]
;11)sentence:[e:996..1004] = [t:996..1004]
;12)sentence:[e:1006..1223] = [t:1006..1223]
;13)sentence:[e:1224..1283] = [t:1224..1283]
;14)sentence:[e:1284..1415] = [t:1284..1415]
;15)sentence:[e:1416..1554] = [t:1416..1554]
;16)sentence:[e:1555..1737] = [t:1555..1737]
;17)sentence:[e:1738..1917] = [t:1738..1917]
;18)sentence:[e:1918..2120] = [t:1918..2120]
;19)sentence:[e:2121..2133] = [t:2121..2133]
;20)sentence:[e:2134..2257] = [t:2134..2257]
;21)section:[e:2261..2305] = [t:2261..2305]

;section 0 Span:0..31
;Surgery  1994 Dec;116(6):1010-6
(SEC
  (FRAG (NNP:[0..7] Surgery) (CD:[9..13] 1994) (IN:[14..22] Dec;116-LRB-)
        (CD:[22..24] 6-RRB-) (CD:[24..29] :1010) (HYPH:[29..30] -)
        (CD:[30..31] 6)))

;sentence 1 Span:36..136
;N-ras mutation: an independent prognostic factor for aggressiveness of
;papillary  thyroid carcinoma.
;[36..41]:gene-rna:"N-ras"
;[107..135]:malignancy:"papillary  thyroid carcinoma"
(SENT
  (NP-HLN
    (NP (NN:[36..41] N-ras) (NN:[42..50] mutation))
    (::[50..51] :)
    (NP
      (NP (DT:[52..54] an) (JJ:[55..66] independent) (JJ:[67..77] prognostic)
          (NN:[78..84] factor))
      (PP (IN:[85..88] for)
        (NP
          (NP (NN:[89..103] aggressiveness))
          (PP (IN:[104..106] of)
            (NP (JJ:[107..116] papillary) (NN:[118..125] thyroid)
                (NN:[126..135] carcinoma))))))
    (.:[135..136] .)))

;section 2 Span:140..198
;Hara H, Fulton N, Yashiro T, Ito K, DeGroot LJ, Kaplan EL.
(SEC
  (FRAG (NNP:[140..144] Hara) (NNP:[145..146] H) (,:[146..147] ,)
        (NNP:[148..154] Fulton) (NNP:[155..156] N) (VBD:[156..157] ,)
        (NNP:[158..165] Yashiro) (NNP:[166..167] T) (,:[167..168] ,)
        (NNP:[169..172] Ito) (NNP:[173..174] K) (,:[174..175] ,)
        (NNP:[176..183] DeGroot) (NNP:[184..186] LJ) (,:[186..187] ,)
        (NNP:[188..194] Kaplan) (NNP:[195..198] EL.)))

;section 3 Span:202..287
;Department of Surgery, University of Chicago Pritzker School of Medicine, Ill
; 60637.
(SEC
  (FRAG (NNP:[202..212] Department) (IN:[213..215] of) (NNP:[216..223] Surgery)
        (,:[223..224] ,) (NNP:[225..235] University) (IN:[236..238] of)
        (NNP:[239..246] Chicago) (NNP:[247..255] Pritzker)
        (NNP:[256..262] School) (IN:[263..265] of) (NNP:[266..274] Medicine)
        (,:[274..275] ,) (NNP:[276..279] Ill) (.:[281..286] 60637)
        (.:[286..287] .)))

;sentence 4 Span:291..302
;BACKGROUND.
(SENT
  (NP (NN:[291..301] BACKGROUND) (.:[301..302] .)))

;sentence 5 Span:303..426
;The clinical importance of point mutations of ras oncogene in  differentiated
;thyroid cancers has not been fully clarified.
;[330..345]:variation-type:"point mutations"
;[349..352]:gene-rna:"ras"
;[366..396]:malignancy:"differentiated thyroid cancers"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[303..306] The) (JJ:[307..315] clinical)
          (NN:[316..326] importance))
      (PP (IN:[327..329] of)
        (NP
          (NP (NN:[330..335] point) (NNS:[336..345] mutations))
          (PP (IN:[346..348] of)
            (NP (NN:[349..352] ras) (NN:[353..361] oncogene)))
          (PP (IN:[362..364] in)
            (NP (VBN:[366..380] differentiated) (NN:[381..388] thyroid)
                (NNS:[389..396] cancers))))))
    (VP (VBZ:[397..400] has) (RB:[401..404] not)
      (VP (VBN:[405..409] been)
        (ADVP (RB:[410..415] fully))
        (VP (VBN:[416..425] clarified)
          (NP-1 (-NONE-:[425..425] *)))))
    (.:[425..426] .)))

;sentence 6 Span:427..544
;The purpose of this  study is to determine the prognostic importance of ras
;mutation in papillary  thyroid carcinoma.
;[499..502]:gene-rna:"ras"
;[515..543]:malignancy:"papillary  thyroid carcinoma"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[427..430] The) (NN:[431..438] purpose))
      (PP (IN:[439..441] of)
        (NP (DT:[442..446] this) (NN:[448..453] study))))
    (VP (VBZ:[454..456] is)
      (S-NOM-PRD
        (NP-SBJ (-NONE-:[456..456] *))
        (VP (TO:[457..459] to)
          (VP (VB:[460..469] determine)
            (NP
              (NP (DT:[470..473] the) (JJ:[474..484] prognostic)
                  (NN:[485..495] importance))
              (PP (IN:[496..498] of)
                (NP (NN:[499..502] ras) (NN:[503..511] mutation))))
            (PP (IN:[512..514] in)
              (NP (JJ:[515..524] papillary) (NN:[526..533] thyroid)
                  (NN:[534..543] carcinoma)))))))
    (.:[543..544] .)))

;sentence 7 Span:545..553
;METHODS.
(SENT
  (NP (NNS:[545..552] METHODS) (.:[552..553] .)))

;sentence 8 Span:554..669
;Tumors of 91 patients with papillary carcinoma were  studied; mean follow-up
;was 14.1 years (range, 1 to 40 years).
;[581..600]:malignancy:"papillary carcinoma"
(SENT
  (S
    (S
      (NP-SBJ-1
        (NP (NNS:[554..560] Tumors))
        (PP (IN:[561..563] of)
          (NP
            (NP (CD:[564..566] 91) (NNS:[567..575] patients))
            (PP (IN:[576..580] with)
              (NP (JJ:[581..590] papillary) (NN:[591..600] carcinoma))))))
      (VP (VBD:[601..605] were)
        (VP (VBN:[607..614] studied)
          (NP-1 (-NONE-:[614..614] *)))))
    (::[614..615] ;)
    (S
      (NP-SBJ (JJ:[616..620] mean) (VB:[621..627] follow) (HYPH:[627..628] -)
              (RP:[628..630] up))
      (VP (VBD:[631..634] was)
        (NP-TMP-PRD (CD:[635..639] 14.1) (NNS:[640..645] years)
          (PRN (-LRB-:[646..647] -LRB-)
            (S
              (NP-SBJ (NN:[647..652] range))
              (,:[652..653] ,)
              (NP-PRD
                (QP (CD:[654..655] 1) (TO:[656..658] to) (CD:[659..661] 40))
                (NNS:[662..667] years)))
            (-RRB-:[667..668] -RRB-)))))
    (.:[668..669] .)))

;sentence 9 Span:670..876
;Patients were  grouped as follows: class I, intrathyroidal disease, n = 21;
;class II, cervical  node metastases, n = 22; class III, extrathyroidal
;disease, n = 19; and class  IV, distant metastases, n = 29.
;[714..736]:malignancy:"intrathyroidal disease"
;[756..781]:malignancy:"cervical  node metastases"
;[802..824]:malignancy:"extrathyroidal disease"
;[849..867]:malignancy:"distant metastases"
(SENT
  (S
    (NP-SBJ-1 (NNS:[670..678] Patients))
    (VP (VBD:[679..683] were)
      (VP (VBN:[685..692] grouped)
        (NP-1 (-NONE-:[692..692] *))
        (PP (IN:[693..695] as)
          (FRAG
            (VP (VBZ:[696..703] follows) (::[703..704] :))
            (FRAG
              (FRAG
                (NP (NN:[705..710] class) (CD:[711..712] I))
                (,:[712..713] ,)
                (NP (JJ:[714..728] intrathyroidal) (NN:[729..736] disease))
                (,:[736..737] ,)
                (S
                  (NP-SBJ (NN:[738..739] n))
                  (VP (SYM:[740..741] =)
                    (NP (CD:[742..744] 21)))))
              (::[744..745] ;)
              (FRAG
                (NP (NN:[746..751] class) (CD:[752..754] II))
                (,:[754..755] ,)
                (NP (JJ:[756..764] cervical) (NN:[766..770] node)
                    (NNS:[771..781] metastases))
                (,:[781..782] ,)
                (S
                  (NP-SBJ (NN:[783..784] n))
                  (VP (SYM:[785..786] =)
                    (NP (CD:[787..789] 22)))))
              (::[789..790] ;)
              (FRAG
                (NP (NN:[791..796] class) (CD:[797..800] III))
                (,:[800..801] ,)
                (NP (JJ:[802..816] extrathyroidal) (NN:[817..824] disease))
                (,:[824..825] ,)
                (S
                  (NP-SBJ (NN:[826..827] n))
                  (VP (SYM:[828..829] =)
                    (NP (CD:[830..832] 19)))))
              (::[832..833] ;) (CC:[834..837] and)
              (FRAG
                (NP (NN:[838..843] class) (CD:[845..847] IV))
                (,:[847..848] ,)
                (NP (JJ:[849..856] distant) (NNS:[857..867] metastases))
                (,:[867..868] ,)
                (S
                  (NP-SBJ (NN:[869..870] n))
                  (VP (SYM:[871..872] =)
                    (NP (CD:[873..875] 29))))))))))
    (.:[875..876] .)))

;sentence 10 Span:877..995
;DNA was analyzed with polymerase chain reaction,  oligonucleotide
;hybridization, and DNA sequence analysis techniques.
;[899..909]:gene-protein:"polymerase"
(SENT
  (S
    (NP-SBJ-1 (NN:[877..880] DNA))
    (VP (VBD:[881..884] was)
      (VP (VBN:[885..893] analyzed)
        (NP-1 (-NONE-:[893..893] *))
        (PP-MNR (IN:[894..898] with)
          (NP
            (NP (NN:[899..909] polymerase) (NN:[910..915] chain)
                (NN:[916..924] reaction))
            (,:[924..925] ,)
            (NP (NN:[927..942] oligonucleotide) (NN:[943..956] hybridization))
            (,:[956..957] ,) (CC:[958..961] and)
            (NP (NN:[962..965] DNA) (NN:[966..974] sequence)
                (NN:[975..983] analysis) (NNS:[984..994] techniques))))))
    (.:[994..995] .)))

;sentence 11 Span:996..1004
;RESULTS.
(SENT
  (NP (NNS:[996..1003] RESULTS) (.:[1003..1004] .)))

;sentence 12 Span:1006..1223
;Thirteen (14.3%) of 91 tumors showed an N-ras point mutation: 4.8% (1 of 21) 
;patients in class I; 4.5% (1 of 22) patients in class II; 15.8% (3 of 19) 
;patients in class III; and 27.8% (8 of 29) patients in class IV.
;[1029..1035]:malignancy:"tumors"
;[1046..1051]:gene-rna:"N-ras"
;[1052..1066]:variation-type:"point mutation"
(SENT
  (S
    (NP-SBJ
      (NP (CD:[1006..1014] Thirteen)
        (PRN (-LRB-:[1015..1016] -LRB-)
          (NP (CD:[1016..1020] 14.3) (NN:[1020..1021] %))
          (-RRB-:[1021..1022] -RRB-)))
      (PP (IN:[1023..1025] of)
        (NP (CD:[1026..1028] 91) (NNS:[1029..1035] tumors))))
    (VP (VBD:[1036..1042] showed)
      (NP (DT:[1043..1045] an) (NN:[1046..1051] N-ras)
         (NN:[1052..1057] point) (NN:[1058..1066] mutation))
      (::[1066..1067] :)
      (NP
        (NP
          (NP (CD:[1068..1071] 4.8) (NN:[1071..1072] %)
            (PRN (-LRB-:[1073..1074] -LRB-)
              (NP
                (NP (CD:[1074..1075] 1))
                (PP (IN:[1076..1078] of)
                  (NP (CD:[1079..1081] 21))))
              (-RRB-:[1081..1082] -RRB-))
            (NNS:[1084..1092] patients))
          (PP (IN:[1093..1095] in)
            (NP (NN:[1096..1101] class) (CD:[1102..1103] I))))
        (::[1103..1104] ;)
        (NP
          (NP (CD:[1105..1108] 4.5) (NN:[1108..1109] %)
            (PRN (-LRB-:[1110..1111] -LRB-)
              (NP
                (NP (CD:[1111..1112] 1))
                (PP (IN:[1113..1115] of)
                  (NP (CD:[1116..1118] 22))))
              (-RRB-:[1118..1119] -RRB-))
            (NNS:[1120..1128] patients))
          (PP (IN:[1129..1131] in)
            (NP (NN:[1132..1137] class) (CD:[1138..1140] II))))
        (::[1140..1141] ;)
        (NP
          (NP (CD:[1142..1146] 15.8) (NN:[1146..1147] %)
            (PRN (-LRB-:[1148..1149] -LRB-)
              (NP
                (NP (CD:[1149..1150] 3))
                (PP (IN:[1151..1153] of)
                  (NP (CD:[1154..1156] 19))))
              (-RRB-:[1156..1157] -RRB-))
            (NNS:[1159..1167] patients))
          (PP (IN:[1168..1170] in)
            (NP (NN:[1171..1176] class) (CD:[1177..1180] III))))
        (::[1180..1181] ;) (CC:[1182..1185] and)
        (NP
          (NP (CD:[1186..1190] 27.8) (NN:[1190..1191] %)
            (PRN (-LRB-:[1192..1193] -LRB-)
              (NP
                (NP (CD:[1193..1194] 8))
                (PP (IN:[1195..1197] of)
                  (NP (CD:[1198..1200] 29))))
              (-RRB-:[1200..1201] -RRB-))
            (NNS:[1202..1210] patients))
          (PP (IN:[1211..1213] in)
            (NP (NN:[1214..1219] class) (CD:[1220..1222] IV))))))
    (.:[1222..1223] .)))

;sentence 13 Span:1224..1283
;Each mutation  changed codon 61 from glutamine to arginine.
;[1229..1237]:variation-event:"mutation"
;[1247..1255]:variation-location:"codon 61"
;[1261..1270]:variation-state-original:"glutamine"
;[1274..1282]:variation-state-altered:"arginine"
(SENT
  (S
    (NP-SBJ (DT:[1224..1228] Each) (NN:[1229..1237] mutation))
    (VP (VBD:[1239..1246] changed)
      (NP (NN:[1247..1252] codon) (CD:[1253..1255] 61))
      (PP (IN:[1256..1260] from)
        (NP (NN:[1261..1270] glutamine)))
      (PP (TO:[1271..1273] to)
        (NP (NN:[1274..1282] arginine))))
    (.:[1282..1283] .)))

;sentence 14 Span:1284..1415
;Patients with distant metastases (8  of 29) had a significantly higher
;incidence of ras mutations than others (5 of  62, p = 0.01).
;[1298..1316]:malignancy:"distant metastases"
;[1368..1371]:gene-rna:"ras"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[1284..1292] Patients))
      (PP (IN:[1293..1297] with)
        (NP (JJ:[1298..1305] distant) (NNS:[1306..1316] metastases)))
      (PRN (-LRB-:[1317..1318] -LRB-)
        (SBAR (CD:[1318..1319] 8))
        (PP (IN:[1321..1323] of)
          (NP (CD:[1324..1326] 29)))
        (-RRB-:[1326..1327] -RRB-)))
    (VP (VBD:[1328..1331] had)
      (NP
        (NP (DT:[1332..1333] a)
          (ADJP (RB:[1334..1347] significantly) (JJR:[1348..1354] higher))
          (NN:[1355..1364] incidence))
        (PP (IN:[1365..1367] of)
          (NP (NN:[1368..1371] ras) (NNS:[1372..1381] mutations)))
        (PP (IN:[1382..1386] than)
          (NP (NNS:[1387..1393] others))))
      (PRN (-LRB-:[1394..1395] -LRB-)
        (FRAG
          (NP
            (NP (CD:[1395..1396] 5))
            (PP (IN:[1397..1399] of)
              (NP (CD:[1401..1403] 62))))
          (,:[1403..1404] ,)
          (S
            (NP-SBJ (NN:[1405..1406] p))
            (VP (SYM:[1407..1408] =)
              (NP (CD:[1409..1413] 0.01)))))
        (-RRB-:[1413..1414] -RRB-)))
    (.:[1414..1415] .)))

;sentence 15 Span:1416..1554
;Patients in classes III and IV also had a higher incidence of  mutations (11
;of 48) than patients in classes I and II (2 of 43, p = 0.01).
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[1416..1424] Patients))
      (PP (IN:[1425..1427] in)
        (NP
          (NP
            (NML-2 (NNS:[1428..1435] classes))
            (CD:[1436..1439] III))
          (CC:[1440..1443] and)
          (NP
            (NML-2 (-NONE-:[1443..1443] *P*))
            (CD:[1444..1446] IV)))))
    (ADVP (RB:[1447..1451] also))
    (VP (VBD:[1452..1455] had)
      (NP
        (NP
          (NP (DT:[1456..1457] a) (JJR:[1458..1464] higher)
              (NN:[1465..1474] incidence))
          (PP (IN:[1475..1477] of)
            (NP (NNS:[1479..1488] mutations))))
        (PRN (-LRB-:[1489..1490] -LRB-)
          (NP
            (NP (CD:[1490..1492] 11))
            (PP (IN:[1493..1495] of)
              (NP (CD:[1496..1498] 48))))
          (-RRB-:[1498..1499] -RRB-))
        (PP (IN:[1500..1504] than)
          (NP
            (NP (NNS:[1505..1513] patients))
            (PP (IN:[1514..1516] in)
              (NP
                (NP
                  (NML-1 (NNS:[1517..1524] classes))
                  (CD:[1525..1526] I))
                (CC:[1527..1530] and)
                (NP
                  (NML-1 (-NONE-:[1530..1530] *P*))
                  (CD:[1531..1533] II)))))))
      (PRN (-LRB-:[1534..1535] -LRB-)
        (FRAG
          (NP
            (NP (CD:[1535..1536] 2))
            (PP (IN:[1537..1539] of)
              (NP (CD:[1540..1542] 43))))
          (,:[1542..1543] ,)
          (S
            (NP-SBJ (NN:[1544..1545] p))
            (VP (SYM:[1546..1547] =)
              (NP (CD:[1548..1552] 0.01)))))
        (-RRB-:[1552..1553] -RRB-)))
    (.:[1553..1554] .)))

;sentence 16 Span:1555..1737
;The  incidence of ras mutations was significantly higher in patients who died
;of  papillary cancer (5 of 15, 33.3%) than in patients who are still alive (8
;of 76,  10.5%) (p = 0.02).
;[1573..1576]:gene-rna:"ras"
;[1637..1653]:malignancy:"papillary cancer"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1555..1558] The) (NN:[1560..1569] incidence))
      (PP (IN:[1570..1572] of)
        (NP (NN:[1573..1576] ras) (NNS:[1577..1586] mutations))))
    (VP (VBD:[1587..1590] was)
      (ADJP-PRD
        (ADJP (RB:[1591..1604] significantly) (JJR:[1605..1611] higher))
        (PP-3 (-NONE-:[1611..1611] *ICH*)))
      (PP (IN:[1612..1614] in)
        (NP
          (NP (NNS:[1615..1623] patients))
          (SBAR
            (WHNP-2 (WP:[1624..1627] who))
            (S
              (NP-SBJ-2 (-NONE-:[1627..1627] *T*))
              (VP (VBD:[1628..1632] died)
                (PP (IN:[1633..1635] of)
                  (NP (JJ:[1637..1646] papillary) (NN:[1647..1653] cancer))))))))
      (PRN (-LRB-:[1654..1655] -LRB-)
        (FRAG
          (NP
            (NP (CD:[1655..1656] 5))
            (PP (IN:[1657..1659] of)
              (NP (CD:[1660..1662] 15))))
          (,:[1662..1663] ,)
          (NP (CD:[1664..1668] 33.3) (NN:[1668..1669] %)))
        (-RRB-:[1669..1670] -RRB-))
      (PP-3 (IN:[1671..1675] than)
        (PP (IN:[1676..1678] in)
          (NP
            (NP (NNS:[1679..1687] patients))
            (SBAR
              (WHNP-1 (WP:[1688..1691] who))
              (S
                (NP-SBJ-1 (-NONE-:[1691..1691] *T*))
                (VP (VBP:[1692..1695] are)
                  (ADVP (RB:[1696..1701] still))
                  (ADJP-PRD (JJ:[1702..1707] alive))
                  (PRN (-LRB-:[1708..1709] -LRB-)
                    (FRAG
                      (NP
                        (NP (CD:[1709..1710] 8))
                        (PP (IN:[1711..1713] of)
                          (NP (CD:[1714..1716] 76))))
                      (,:[1716..1717] ,)
                      (NP (CD:[1719..1723] 10.5) (NN:[1723..1724] %)))
                    (-RRB-:[1724..1725] -RRB-))))))))
      (PRN (-LRB-:[1726..1727] -LRB-)
        (S
          (NP-SBJ (NN:[1727..1728] p))
          (VP (SYM:[1729..1730] =)
            (NP (CD:[1731..1735] 0.02))))
        (-RRB-:[1735..1736] -RRB-)))
    (.:[1736..1737] .)))

;sentence 17 Span:1738..1917
;Kaplan-Meier survival curves also showed a greater mortality  from tumor (p <
;0.05) and a higher recurrence rate (p < 0.01) in ras-positive  tumors than in
;the ras-negative group.
;[1805..1810]:malignancy:"tumor"
;[1865..1868]:gene-rna:"ras"
;[1879..1885]:malignancy:"tumors"
;[1898..1901]:gene-rna:"ras"
(SENT
  (S
    (NP-SBJ
      (NML (NNP:[1738..1744] Kaplan) (HYPH:[1744..1745] -)
           (NNP:[1745..1750] Meier))
      (NN:[1751..1759] survival) (NNS:[1760..1766] curves))
    (ADVP (RB:[1767..1771] also))
    (VP (VBD:[1772..1778] showed)
      (NP
        (NP
          (NP
            (NP (DT:[1779..1780] a) (JJR:[1781..1788] greater)
                (NN:[1789..1798] mortality))
            (PP-1 (-NONE-:[1798..1798] *ICH*)))
          (PP (IN:[1800..1804] from)
            (NP (NN:[1805..1810] tumor)))
          (PRN (-LRB-:[1811..1812] -LRB-)
            (S
              (NP-SBJ (NN:[1812..1813] p))
              (VP (SYM:[1814..1815] <)
                (NP (CD:[1816..1820] 0.05))))
            (-RRB-:[1820..1821] -RRB-)))
        (CC:[1822..1825] and)
        (NP
          (NP
            (NP (DT:[1826..1827] a) (JJR:[1828..1834] higher)
                (NN:[1835..1845] recurrence) (NN:[1846..1850] rate))
            (PP-1 (-NONE-:[1850..1850] *ICH*)))
          (PRN (-LRB-:[1851..1852] -LRB-)
            (S
              (NP-SBJ (NN:[1852..1853] p))
              (VP (SYM:[1854..1855] <)
                (NP (CD:[1856..1860] 0.01))))
            (-RRB-:[1860..1861] -RRB-))))
      (PP-1 (IN:[1862..1864] in)
        (NP
          (ADJP (NN:[1865..1868] ras) (HYPH:[1868..1869] -)
                (JJ:[1869..1877] positive))
          (NNS:[1879..1885] tumors))))
    (PP (IN:[1886..1890] than)
      (PP (IN:[1891..1893] in)
        (NP (DT:[1894..1897] the)
          (ADJP (NN:[1898..1901] ras) (HYPH:[1901..1902] -)
                (JJ:[1902..1910] negative))
          (NN:[1911..1916] group))))
    (.:[1916..1917] .)))

;sentence 18 Span:1918..2120
;Finally, in studies by multivariate  analyses, positive ras mutation and age
;were shown to be two independent  prognostic factors for prediction of death
;from papillary cancer and recurrence  of cancer.
;[1974..1977]:gene-rna:"ras"
;[2077..2093]:malignancy:"papillary cancer"
;[2113..2119]:malignancy:"cancer"
(SENT
  (S
    (ADVP (RB:[1918..1925] Finally))
    (,:[1925..1926] ,)
    (PP (IN:[1927..1929] in)
      (NP
        (NP (NNS:[1930..1937] studies))
        (PP (IN:[1938..1940] by)
          (NP (JJ:[1941..1953] multivariate) (NNS:[1955..1963] analyses)))))
    (,:[1963..1964] ,)
    (NP-SBJ-1
      (NP (JJ:[1965..1973] positive) (NN:[1974..1977] ras)
          (NN:[1978..1986] mutation))
      (CC:[1987..1990] and)
      (NP (NN:[1991..1994] age)))
    (VP (VBD:[1995..1999] were)
      (VP (VBN:[2000..2005] shown)
        (S
          (NP-SBJ-1 (-NONE-:[2005..2005] *))
          (VP (TO:[2006..2008] to)
            (VP (VB:[2009..2011] be)
              (NP-PRD
                (NP (CD:[2012..2015] two) (JJ:[2016..2027] independent)
                    (JJ:[2029..2039] prognostic) (NNS:[2040..2047] factors))
                (PP (IN:[2048..2051] for)
                  (NP
                    (NP (NN:[2052..2062] prediction))
                    (PP (IN:[2063..2065] of)
                      (NP
                        (NP
                          (NP (NN:[2066..2071] death))
                          (PP (IN:[2072..2076] from)
                            (NP (JJ:[2077..2086] papillary)
                                (NN:[2087..2093] cancer))))
                        (CC:[2094..2097] and)
                        (NP
                          (NP (NN:[2098..2108] recurrence))
                          (PP (IN:[2110..2112] of)
                            (NP (NN:[2113..2119] cancer))))))))))))))
    (.:[2119..2120] .)))

;sentence 19 Span:2121..2133
;CONCLUSIONS.
(SENT
  (NP (NNS:[2121..2132] CONCLUSIONS) (.:[2132..2133] .)))

;sentence 20 Span:2134..2257
;Mutation of N-ras gene at codon 61 is an independent  prognostic factor for
;aggressiveness of papillary thyroid carcinomas.
;[2134..2142]:variation-event:"Mutation"
;[2146..2151]:gene-rna:"N-ras"
;[2160..2168]:variation-location:"codon 61"
;[2228..2256]:malignancy:"papillary thyroid carcinomas"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[2134..2142] Mutation))
      (PP (IN:[2143..2145] of)
        (NP (NN:[2146..2151] N-ras) (NN:[2152..2156] gene)))
      (PP (IN:[2157..2159] at)
        (NP (NN:[2160..2165] codon) (CD:[2166..2168] 61))))
    (VP (VBZ:[2169..2171] is)
      (NP-PRD
        (NP (DT:[2172..2174] an) (JJ:[2175..2186] independent)
            (JJ:[2188..2198] prognostic) (NN:[2199..2205] factor))
        (PP (IN:[2206..2209] for)
          (NP
            (NP (NN:[2210..2224] aggressiveness))
            (PP (IN:[2225..2227] of)
              (NP (JJ:[2228..2237] papillary) (NN:[2238..2245] thyroid)
                  (NNS:[2246..2256] carcinomas)))))))
    (.:[2256..2257] .)))

;section 21 Span:2261..2305
;PMID: 7985080 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2261..2265] PMID) (::[2265..2266] :) (CD:[2267..2274] 7985080)
        (IN:[2275..2276] -LSB-) (NNP:[2276..2282] PubMed) (HYPH:[2283..2284] -)
        (JJ:[2285..2292] indexed) (IN:[2293..2296] for)
        (NNP:[2297..2305] MEDLINE-RSB-)))
